A Phase 4 interventional study of OAC will be discontinued for the duration of the trial in Atrial Fibrillation, Left Atrial Appendage Absent and Anticoagulant Adverse Reaction, sponsored by Odense University Hospital. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atrial Fibrillation by Odense University Hospital — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Odense University Hospital.
Among the 10 studies in Atrial Fibrillation by Odense University Hospital, this one is the only one that started in 2024, is the only one in phase 4, and was the 9th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 10 studies in Atrial Fibrillation by Odense University Hospital are open now, in 1 country. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 60–95
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,220 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 141 across the 6 interventional studies, 182 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Atrial Fibrillation by Odense University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed.
The ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OAC stopped for the duration of the trial
Drug: OAC will be discontinued for the duration of the trial
OAC continued for the duration of the trial
Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Number of participants with ischemic strokes, peripheral arterial embolisms and major bleedings
Composite endpoint including the occurrence of ischemic stroke, peripheral arterial embolism, and major bleeding (ISTH definition)
Time frame: After 128 primary outcome events (approx 4 years)
Severity of stroke
According to Scandinavian Stroke Scale (0-58), lower scores mean worse outcomes
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of transient ischemic attacks
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of all-cause stroke
Time frame: After 128 primary outcome events (approx 4 years)
Rate of all-cause mortality
Time frame: After 128 primary outcome events (approx 4 years)
Rate of cardiovascular mortality
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of minor bleeding
All types of bleeding leading to hospital contact
Time frame: After 128 primary outcome events (approx 4 years)
Number of participants who receive blood transfusion
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of myocardial infarction
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of deep venous thrombosis
Time frame: After 128 primary outcome events (approx 4 years)
Occurence of pulmonary embolism
Time frame: After 128 primary outcome events (approx 4 years)
Health-related Quality of Life (HRQOL)
EQ-5D-5L (EuroQol-5 Dimensions-5 Levels) score to evaluate generic HRQOL (0-100). Higher scores mean better quality of life.
Time frame: Baseline (day 0) and 1 and 2 years after inclusion
Patient-reported satisfaction with overall medical treatment
Treatment Satisfaction Questionnaire (TSQM) to evaluate satisfaction related to their overall medical treatment. TSQM scoring is by domain and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100. Higher scores indicate higher patient satisfaction with medication.
Time frame: Baseline (day 0) and 1 and 2 years after inclusion
Patient-reported satisfaction with anticoagulant treatment
Anti-Clot Treatment Scale (ACTS) questionnaire to evaluate satisfaction related to oral anticoagulant treatment. The ACTS Burdens total score ranges from 12 to 60, and the ACTS Benefits total score ranges from 3 to 15. Higher ACTS Burdens and Benefits scores indicate greater satisfaction with treatment.
Time frame: Baseline (day 0) after inclusion
Plan to share: No
Started May 2024 (actual). Primary completion is estimated for Mar 2028, 45 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 45 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.